KPC(600422) 华福证券·2025-02-19 12:23Investment Rating - The report maintains a "Buy" rating for Kunming Pharmaceutical Group (600422.SH) [2][6] Core Views - The company is expected to achieve a revenue of 8.4 billion yuan in 2024, representing a 9.1% increase compared to the previous adjustment, and a net profit of 650 million yuan, reflecting a 45.7% increase [4][6] - The integration of Huaren Shenghuo is expected to enhance the company's competitive position in the cardiovascular treatment market and improve its performance in the aging health and chronic disease management sectors [5][6] - The company has successfully won bids for its key products in the national traditional Chinese medicine procurement, which is anticipated to expand its sales reach and enhance brand recognition [6][6] Financial Forecasts - Revenue projections for 2024, 2025, and 2026 are 8.4 billion yuan, 9.22 billion yuan, and 10.11 billion yuan respectively, with growth rates of 9%, 10%, and 10% [6][7] - Net profit forecasts for the same years are 650 million yuan, 760 million yuan, and 930 million yuan, with growth rates of 46%, 17%, and 23% [6][7] - The report indicates an expected EPS of 0.86 yuan for 2024, increasing to 1.00 yuan in 2025 and 1.23 yuan in 2026 [7][7]